Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
Lay Description
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use the pen to inject the study medicine in a skinfold once a week. The study will last for about 2.5 to 5 years. Participants will have up to 25 clinic visits with the study doctor.
Category
- Heart, Vascular and Blood
- Obesity
- IRB Number
- 20180795HU
- NCT Number
- NCT03574597
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Over 45 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Male or female, age greater than or equal to 45 years at the time of signing informed consent
- Body mass index (BMI) greater than or equal to 27 kg/m^2
- Have established cardiovascular (CV) disease as evidenced by at least one of the following: prior myocardial infarction; prior stroke (ischemic or haemorrhagic stroke); or symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) less than 0.85 (at rest), or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease
Exclusion Criteria
- Any of the following: myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening
- HbA1c greater than or equal to 48 mmol/mol (6.5 %) as measured by the central laboratory at screening
- History of type 1 or type 2 diabetes (history of gestational diabetes is allowed)
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu
Regulatory Point of Contact
Devjit Tripathy
(210) 567-6691
tripathy@uthscsa.edu
Local Recruitment Point of Contact
Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu
Local Recruitment Point of Contact
Devjit Tripathy
(210) 567-6691
tripathy@uthscsa.edu
Principal Investigator
Devjit Tripathy